AR053984A1 - Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas - Google Patents

Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas

Info

Publication number
AR053984A1
AR053984A1 ARP050104620A ARP050104620A AR053984A1 AR 053984 A1 AR053984 A1 AR 053984A1 AR P050104620 A ARP050104620 A AR P050104620A AR P050104620 A ARP050104620 A AR P050104620A AR 053984 A1 AR053984 A1 AR 053984A1
Authority
AR
Argentina
Prior art keywords
inhibitor
treatment
cinasa
bcr
protein
Prior art date
Application number
ARP050104620A
Other languages
English (en)
Spanish (es)
Inventor
Francis Y Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR053984A1 publication Critical patent/AR053984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP050104620A 2004-11-04 2005-11-03 Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas AR053984A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62493704P 2004-11-04 2004-11-04
US63212204P 2004-12-01 2004-12-01
US64972205P 2005-02-03 2005-02-03
US70362805P 2005-07-29 2005-07-29

Publications (1)

Publication Number Publication Date
AR053984A1 true AR053984A1 (es) 2007-05-30

Family

ID=36337059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104620A AR053984A1 (es) 2004-11-04 2005-11-03 Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas

Country Status (13)

Country Link
US (2) US20060094728A1 (https=)
EP (1) EP1812432A4 (https=)
JP (1) JP2008519049A (https=)
KR (1) KR20070073864A (https=)
AR (1) AR053984A1 (https=)
AU (1) AU2005304863A1 (https=)
BR (1) BRPI0515721A (https=)
CA (1) CA2586649A1 (https=)
MX (1) MX2007005115A (https=)
NO (1) NO20072179L (https=)
RU (1) RU2007120710A (https=)
TW (1) TW200628156A (https=)
WO (1) WO2006052810A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
ATE505192T1 (de) * 2005-06-09 2011-04-15 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
WO2007047919A2 (en) 2005-10-20 2007-04-26 University Of South Florida Treatment of restenosis and stenosis with dasatinib
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2508523B2 (en) * 2007-10-23 2019-04-17 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN101891738B (zh) * 2010-02-08 2011-09-28 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
CN102643275B (zh) * 2011-02-21 2016-04-20 江苏先声药物研究有限公司 一种达莎替尼n-6晶型新的制备方法
CN102838594B (zh) * 2011-06-24 2015-06-24 南京圣和药业股份有限公司 一种达沙替尼的制备及精制方法
CA2937992A1 (en) * 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
AU2023373917A1 (en) 2022-11-02 2025-05-01 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
KR20260016906A (ko) 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법
WO2025188914A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Tyrosine phosphatase inhibitor 1 (tpi-1) derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen

Also Published As

Publication number Publication date
AU2005304863A1 (en) 2006-05-18
US20090093495A1 (en) 2009-04-09
WO2006052810A3 (en) 2007-02-08
MX2007005115A (es) 2007-06-26
CA2586649A1 (en) 2006-05-18
EP1812432A2 (en) 2007-08-01
TW200628156A (en) 2006-08-16
US20060094728A1 (en) 2006-05-04
JP2008519049A (ja) 2008-06-05
RU2007120710A (ru) 2008-12-10
WO2006052810A2 (en) 2006-05-18
KR20070073864A (ko) 2007-07-10
BRPI0515721A (pt) 2008-08-05
NO20072179L (no) 2007-05-31
EP1812432A4 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
CO6450624A2 (es) Compuestos vinil indazolilo
GT201100181A (es) "inhibidores de proteina cinasa"
NO20034713L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)- benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin og et kjemoterapeutiskmiddel
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
ATE521354T1 (de) Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
JP2009532438A5 (https=)
DE60308337D1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten
AR054445A1 (es) Formulaciones de un inhibidor de src/abl
CO2018006929A2 (es) "compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer"
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
TNSN06182A1 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
AR111255A1 (es) Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio
DE60319211D1 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
IS8139A (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
RU2007135284A (ru) Фармацевтические комбинации ингибиторов киназ bcr-abl и raf
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
NZ610401A (en) Inhibitors of the mutant form of kit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal